BioAge Labs (BIOA) Current Deferred Revenue (2023 - 2026)

BioAge Labs has disclosed Current Deferred Revenue across 4 years of filings, most recently posting $6.2 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $6.2 million, down 24.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.2 million (down 24.34% YoY), and the FY2025 annual result was $5.8 million, down 26.48% from the prior year.
• Current Deferred Revenue came in at $6.2 million for Q1 2026 at BioAge Labs, up from $5.8 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $8.2 million in Q1 2025 to a low of $3.3 million in Q4 2023.
• The 4-year median for Current Deferred Revenue is $7.5 million (2025), against an average of $6.6 million.
• Across the five-year window, Current Deferred Revenue surged 136.22% in 2024 and decreased 26.48% in 2025, its largest moves.
• BioAge Labs' Current Deferred Revenue stood at $3.3 million in 2023, then jumped by 136.22% to $7.8 million in 2024, then fell by 26.48% to $5.8 million in 2025, then advanced by 7.59% to $6.2 million in 2026.
• The last three Current Deferred Revenue figures came in at $6.2 million (Q1 2026), $5.8 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.